Exploring the Social Determinants of Mental Health

A look at the theme for the 2022 American Psychiatric Association Annual Meeting.

Related Videos

Related Content

Advertisement

March 4th 2025

Leadership in Child & Adolescent Psychiatry: In Conversation With Vincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych

Leah Kuntz Vincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych

May 6th 2014

Bipolar Disorder: Update on Diagnosis

S. Nassir Ghaemi, MD, MPH

February 14th 2025

Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings

Megan McSweeney

May 2nd 2014

Persistent Loneliness: A Relentless-and Prevalent-Problem

Donna M. Sudak, MD

February 13th 2025

Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis

Megan McSweeney

February 12th 2025

AXS-05 Demonstrates Efficacy and Manageable Adverse Effects in Major Depressive Disorder Treatment

Megan McSweeney

Related Content

Advertisement

March 4th 2025

Leadership in Child & Adolescent Psychiatry: In Conversation With Vincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych

Leah Kuntz Vincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych

May 6th 2014

Bipolar Disorder: Update on Diagnosis

S. Nassir Ghaemi, MD, MPH

February 14th 2025

Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings

Megan McSweeney

May 2nd 2014

Persistent Loneliness: A Relentless-and Prevalent-Problem

Donna M. Sudak, MD

February 13th 2025

Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis

Megan McSweeney

February 12th 2025

AXS-05 Demonstrates Efficacy and Manageable Adverse Effects in Major Depressive Disorder Treatment

Megan McSweeney